Shareholders and investors were relieved that Protalix BioTherapeutics (NYSE:PLX) will wait until after the FDA approves of taliglucerase, which a large number believe will happen.
Protalix has recently filed a $150 million shelf offering which they have now abandoned.
The PDUFA date for taliglucerase is February 25.
Wells Fargo (NYSE:WFC) also recently noted that revenues for Genzyme (Nasdaq:GENZ) from Cerezyme were lower than expected for the fourth quarter, citing supply issues. They consider that a positive for Protalix.
Protalix closed Wednesday at $10.19, up $0.07, or 0.69 percent.
Thursday, January 13, 2011
Protalix BioTherapeutics (NYSE:PLX) Up as They Wait Till After FDA Approval to Raise Capital
Labels:
Protalix BioTherapeutics,
Wells Fargo
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment